玻璃体腔注射曲安奈德治疗葡萄膜炎继发黄斑水肿的临床应用  

Clinical Application of IVTA Treatment for ME Caused by Uveitis

作　　者：郑利民[1] 罗立勤[1] 杜鹏程[1] 杨建华[1] 王俊琴[1] 

机构地区：[1]包头医学院第一附属医院眼科,内蒙古包头014010

出　　处：《中国伤残医学》2012年第8期27-28,共2页Chinese Journal of Trauma and Disability Medicine

摘　　要：目的:通过观察玻璃体腔注射曲安奈德(TA)治疗葡萄膜炎继发黄斑水肿的临床疗效。方法:回顾性分析18例眼科常规检查及经FFA和频域OCT查均确诊为葡萄膜炎继发黄斑水肿,视力≤0.6,黄斑中心凹厚度(CMT)≥250μm的患者18只眼纳入观察,进行玻璃体腔注射TA(4mg,0.1ml)治疗。比较治疗前和治疗后1天及1,2,4,8,12周最佳矫正视力(BCVA)改变;治疗前和治疗后1,2,4,8,12周的黄斑中心凹厚度(CMT)的改变。结果:在治疗后视显提高,术后各时间点(P=0.000)均具有统计学意义,BCVA各点分别为:4周0.6537±0.1421;8周0.7438±0.1153;12周0.7139±0.2158,视力基本持平,术后1周有14例视力提高大于3行,占77.78%。CMT方面,较基线比,在治疗后CMT明显降低,术后各时间点(P=0.000)均具有统计学意义。BCVA与CMT呈负相关。结论:玻璃体腔注射TA治疗葡萄膜炎继发黄斑水肿均可明显改善,减轻黄斑水肿。BCVA与CMT呈负相关,CMT是反映治疗效果的敏感指标。Objective： To observe the efficiency of IVTA for the treatment of ME caused by uveitis. Methods： A total of 30 eyes with ME second to uveitis were observed. All patients were diagnosed expecially by FFA and spectra domain OCT, with vision≤ 0.6 and CMT≥250/μm. All received intravitreal injection of 4mg/0.1ml of TA.BCVA and CMT were compared before and after treatment. Results： After treatment,BCVA were significantly increased in each time point（P=0.000）, BCVA in 4 （BCVA=0.6537 ± 0.1421）, 8 （BCVA=0.7438 ± 0.1153）, 12 （BCVA=0.7139 ± 0.2158） weeks, were similar. After treatment, compared with baseline, the changes of CMT were significantly increased in each time point（P=0.000）. Conelusions： IVTA for the treatment of ME in uveitis could increase BCVA and reduce ME instinctively. CMT can reveal the effect of treatment as a sensitive indicator.

关 键 词：葡萄膜炎 曲安奈德 黄斑水肿 频域OCT 

分 类 号：R773.4[医药卫生—眼科]